US Patent Issued to Ludwig Institute for Cancer Research, Centre Hospitalier Universitaire Vaudois, Universite de Lausanne on May 13 for "Anti-TEM1 antibodies and antigen-binding portions thereof" (Swiss Inventors)

ALEXANDRIA, Va., June 12 -- United States Patent no. 12,297,276, issued on May 13, was assigned to Ludwig Institute for Cancer Research Ltd (Zurich), Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland) and Universite de Lausanne (Lausanne, Switzerland).

"Anti-TEM1 antibodies and antigen-binding portions thereof" was invented by Steven M. Dunn (Epalinges, Switzerland), Julie K. Fierle (Epalinges, Switzerland) and George Coukos (Epalinges, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions there...